Memorial Sloan-Kettering Cancer Center (MSKCC) is a free-standing institution founded as the New York Cancer Hospital in 1884 and now located in the upper east side of New York City, adjacent to the health sciences campuses of Cornell University Medical College and Rockefeller University. The Center's mission is the progressive control and cure of cancer through programs of research, patient care, and education. MSKCC is dedicated to the study of cancer through a defined spectrum of laboratory research, an interactive program spanning basic and clinical science, a strong capability for basic-to-clinic technology transfer, a structured program of clinical cancer research, state-of-the art clinical programs, including in-patient and out-patient clinical care, community care focused on early diagnosis and specific cancers and a strategically selected set of priorities in population-based research that addresses issues of both local and national importance. The research activities of MSKCC are administratively organized in seven research programs: Molecular Biology, Cell Biology, Cellular Biochemistry and Biophysics, Immunology, Molecular Pharmacology and Therapeutics, Clinical Research and Cancer Prevention and Control. These Programs are supported by 13 CCSG-supported Core Facilities as well as others supported entirely by institutional resources. The Core Facilities for which CCSG support is requested are: General Animal, Animal Health, Transgenic Mouse, Glassware Washing, Media Preparation, Flow Cytometry, Microchemistry, Molecular Cytology, Analytical Pharmacology, Human Tissue Procurement, Research Pharmacy Support, Biostatistics, and Clinical Research Support. Funds are also requested for Clinical Protocol Scientific Review and Monitoring and for Development.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-36
Application #
6341801
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1977-01-01
Project End
2002-12-31
Budget Start
2001-01-01
Budget End
2001-12-31
Support Year
36
Fiscal Year
2001
Total Cost
$6,030,281
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Shoag, Jonathan; Liu, Deli; Blattner, Mirjam et al. (2018) SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. J Clin Invest 128:381-386
Assel, Melissa J; Gerdtsson, Axel; Thorek, Daniel L J et al. (2018) Long-term prediction of prostate cancer diagnosis and death using PSA and obesity related anthropometrics at early middle age: data from the malmö preventive project. Oncotarget 9:5778-5785
Katsoulakis, Evangelia; Leeman, Jonathan E; Lok, Benjamin H et al. (2018) Long-term outcomes in oral cavity squamous cell carcinoma with adjuvant and salvage radiotherapy after surgery. Laryngoscope 128:2539-2545
Breitbart, William (2018) In Memoriam: Jimmie C. Holland, MD, 1928-2017. Palliat Support Care 16:124-126
Hoseini, Sayed Shahabuddin; Guo, Hongfen; Wu, Zhihao et al. (2018) A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia. Blood Adv 2:1250-1258
Grkovski, Milan; Fanchon, Louise; Pillarsetty, Naga Vara Kishore et al. (2018) 18F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model. EJNMMI Res 8:53
Tollinche, Luis; Tan, KaySee; Han, Austin et al. (2018) Analyzing Volatile Anesthetic Consumption by Auditing Fresh Gas Flow: An Observational Study at an Academic Hospital. Int J Anesth Anesth 5:
Lin, Ching-Jung; Hu, Fuqu; Dubruille, Raphaelle et al. (2018) The hpRNA/RNAi Pathway Is Essential to Resolve Intragenomic Conflict in the Drosophila Male Germline. Dev Cell 46:316-326.e5
Tadros, Audree B; Wen, Hannah Y; Morrow, Monica (2018) Breast Cancers of Special Histologic Subtypes Are Biologically Diverse. Ann Surg Oncol 25:3158-3164
Chan, Chang S; Laddha, Saurabh V; Lewis, Peter W et al. (2018) ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nat Commun 9:4158

Showing the most recent 10 out of 8799 publications